| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
MorphoSys AG (XETRA: MOR)
MOR Technical Analysis
3
| As on 9th Jun 2023 MOR STOCK Price closed @ 27.56 and we RECOMMEND Buy for LONG-TERM with Stoploss of 21.79 & Buy for SHORT-TERM with Stoploss of 26.51 we also expect STOCK to react on Following IMPORTANT LEVELS. |
MORSTOCK Price
| Open | 27.72 | Change | Price | % |
| High | 27.96 | 1 Day | -0.21 | -0.76 |
| Low | 26.80 | 1 Week | 3.76 | 15.80 |
| Close | 27.56 | 1 Month | 8.49 | 44.52 |
| Volume | 175915 | 1 Year | -4.74 | -14.67 |
| 52 Week High 33.32 | 52 Week Low 12.05 | ||||
XETRA Germany Most Active Stocks
| LHAR | 2.05 | -20.23% |
| BBVA | 5.00 | -2.72% |
| BBVA | 5.00 | -2.72% |
| BBVA | 5.00 | -2.72% |
| BVBA | 0.02 | -60.00% |
| SNH | 0.16 | 6.67% |
| SNH | 0.16 | 6.67% |
| SNH | 0.16 | 6.67% |
| AT1 | 1.15 | 5.50% |
| AT1 | 1.15 | 5.50% |
XETRA Germany Top Gainers Stocks
XETRA Germany Top Losers Stocks
| MOR Daily Charts |
MOR Intraday Charts |
Whats New @ Bazaartrend |
MOR Free Analysis |
|
|
MOR Important Levels Intraday
| RESISTANCE | 29.80 |
| RESISTANCE | 29.08 |
| RESISTANCE | 28.64 |
| RESISTANCE | 28.19 |
| SUPPORT | 26.93 |
| SUPPORT | 26.48 |
| SUPPORT | 26.04 |
| SUPPORT | 25.32 |
MOR Forecast April 2024
| 4th UP Forecast | 43.3 |
| 3rd UP Forecast | 38.25 |
| 2nd UP Forecast | 35.13 |
| 1st UP Forecast | 32.01 |
| 1st DOWN Forecast | 23.11 |
| 2nd DOWN Forecast | 19.99 |
| 3rd DOWN Forecast | 16.87 |
| 4th DOWN Forecast | 11.82 |
MOR Weekly Forecast
| 4th UP Forecast | 37.06 |
| 3rd UP Forecast | 34.01 |
| 2nd UP Forecast | 32.13 |
| 1st UP Forecast | 30.25 |
| 1st DOWN Forecast | 24.87 |
| 2nd DOWN Forecast | 22.99 |
| 3rd DOWN Forecast | 21.11 |
| 4th DOWN Forecast | 18.06 |
MOR Forecast2024
| 4th UP Forecast | 69.61 |
| 3rd UP Forecast | 56.12 |
| 2nd UP Forecast | 47.79 |
| 1st UP Forecast | 39.45 |
| 1st DOWN Forecast | 15.67 |
| 2nd DOWN Forecast | 7.33 |
| 3rd DOWN Forecast | -1 |
| 4th DOWN Forecast | -14.49 |
MorphoSys AG ( XETRA Germany Symbol : MOR )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
MOR Business Profile
MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany. Address: Semmelweisstrasse 7, Planegg, Germany, 82152
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service